These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7719378)

  • 1. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.
    Meffert M; Hanninen EL; Menzel T; Schomburg A; Duensing S; Dallmann I; Grosse J; Vocke S; Buer J; Deckert M
    Cancer Biother; 1994; 9(4):307-16. PubMed ID: 7719378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivo.
    Meffert M; Duensing S; Atzpodien J
    Cancer Biother Radiopharm; 1997 Jun; 12(3):149-55. PubMed ID: 10851461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
    Finck-Seelen ; Lampert R; Brandt L
    Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
    Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
    Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
    Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
    Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
    Schomburg A; Kirchner H; Atzpodien J
    Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
    J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid cytokine release in cancer patients treated with interleukin-2.
    Weidmann E; Bergmann L; Stock J; Kirsten R; Mitrou PS
    J Immunother (1991); 1992 Aug; 12(2):123-31. PubMed ID: 1504053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.